| Name | Title | Contact Details |
|---|
Hackenberg and Associates is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EMINENT Services Corporation is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SWORD Health is the world`s fastest growing virtual musculoskeletal (MSK) care provider, on a mission to free two billion people from chronic and post-surgical pain. The company`s clinical-grade virtual therapy platform pairs expert physical therapists with FDA-listed wearable technology to deliver a personalized treatment plan that is more effective, easier and less expensive than traditional physical therapy. SWORD Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. Since launching in 2015, SWORD Health has worked with insurers, health systems and employers in the U.S, Europe and Australia to make quality physical therapy more accessible to everyone. SWORD Health has offices in New York City, Chicago, Salt Lake City, Sydney and Porto.
Acuity Healthcare is an employee-owned Long Term Acute Care (LTAC) hospital company, founded in 2001. Acuity is the only company with the flexibility to tailor its services to meet the specific needs of its clients. We understand how LTAC services can, and should work, within today`s "post-acute continuum". This innate flexibility and core understanding of the complexities of the healthcare continuum has enabled Acuity to develop a broad array of services that include: Joint Ventured ownership of its LTAC hospitals with area physicians and local hospitals, full LTAC contract management services, full LTAC contract financial management services and complete LTAC consulting services.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.